论文信息 - More is not always better for novel hepatitis B therapies. - 字舞流文

More is not always better for novel hepatitis B therapies.

X. Forns | S. Lens

[1] K. Agarwal,et al. New Approaches to Chronic Hepatitis B. , 2023, The New England journal of medicine.

[2] M. Biermer,et al. A case of HBV-induced liver failure in the REEF-2 Phase 2 trial: Implications for finite treatment strategies in HBV 'cure'. , 2022, Journal of hepatology.

[3] T. Baumert,et al. Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives , 2022, Journal of clinical medicine.

[4] X. Forns,et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: An international, multi-center, multi-ethnic cohort (RETRACT-B study). , 2021, Gastroenterology.

[5] Q. Ning,et al. The potential immune regulation benefit of CpAMs beyond HBV suppression. , 2021, The lancet. Gastroenterology & hepatology.

[6] M. Manns,et al. RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection , 2020, Hepatology.